Smiling older man hiking in the hills with binoculars and a backpack

Bringing hope

through the discovery and development of integrin-based therapies in underserved areas of medical need

Now enrolling!

See if you may qualify

Now enrolling!

See if you may qualify

Investigating NOVEL, TARGETED INTEGRIN-BASED THERAPIES FOR SERIOUS DISEASES

Our highly experienced drug development and clinical teams are focused on delivering new therapeutic options. Our lead drug candidate, PLN-101095, is an α_vβ₈ /α_vβ₁ integrin inhibitor currently being investigated in the FORTIFY trial for people with advanced or metastatic solid tumors.

Explore our pipeline

Illustration of a solid tumor cell enclosed in a glowing mesh sphere

Expanding our opportunities

We are also advancing additional programs that draw on the full potential of our proprietary integrin-based drug discovery and delivery platform.

Learn about our science

Pliant scientist in a lab coat and blue gloves pipetting a sample into a small tube

Latest News

11-09-2026

Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

10-29-2026

Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

10-20-2026

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi)

Healthy woman with curly hair leaning on a rooftop railing with a city skyline behind her

Careers & Culture

We are passionate about bringing breakthrough therapies to people whose lives have been disrupted by serious diseases. See what makes Pliant such an inspiring and exciting place to work.